Insulin Resistance: Comprehensive Management Strategies
Insulin resistance (IR) underlies type 2 diabetes, metabolic syndrome, PCOS, and cardiovascular disease. Management targets improved insulin sensitivity through lifestyle, pharmacotherapy, and treatment of underlying drivers.
Diagnostic Criteria
- HOMA-IR: (Fasting insulin × Fasting glucose)/405; >2.5 suggests IR
- Triglyceride/HDL ratio: >3.5 correlates with IR
- Clinical markers: Acanthosis nigricans, skin tags, central obesity, hypertension, dyslipidemia
- OGTT with insulin: Gold standard for research
Lifestyle Interventions (Cornerstone)
Weight Management
- 5-10% weight loss → 30-60% improvement in insulin sensitivity
- Target: 0.5-1 kg/week via 500-750 kcal deficit
- Visceral fat reduction more important than total weight
Nutrition
- Pattern: Mediterranean, DASH, low-glycemic load, moderate carb (40-45%)
- Prioritize: Fiber (≥30g), omega-3s, polyphenols, magnesium, chromium
- Limit: Refined carbs, added sugars, saturated/trans fats, alcohol
- Timing: Time-restricted eating (10-12h window) may improve circadian insulin sensitivity
Physical Activity
- Aerobic: 150-300 min/week moderate (brisk walk, cycle, swim)
- Resistance: 2-3×/week all major muscle groups (muscle = major glucose disposal site)
- HIIT: Time-efficient, potent insulin sensitizer
- Postprandial walks: 10-15 min after meals blunts glucose spikes
- Reduce sedentary time: Stand/walk every 30 min
Sleep & Stress
- 7-9 hours; treat sleep apnea (major IR driver)
- Stress → cortisol → hepatic gluconeogenesis, visceral adiposity
- Mindfulness, CBT, nature exposure reduce cortisol
Smoking Cessation
Smoking increases IR via inflammation, oxidative stress, sympathetic activation. Quitting improves sensitivity within weeks.
Pharmacotherapy
| Agent | Mechanism | Indication | Key Considerations |
|---|---|---|---|
| Metformin | ↓ Hepatic gluconeogenesis, ↑ AMPK, ↑ GLUT4 | First-line for IR, prediabetes, T2DM, PCOS | GI side effects; B12 monitoring; contraindicated eGFR<30 |
| TZDs (pioglitazone) | PPAR-γ agonist → ↑ adiponectin, ↑ insulin sensitivity | Adjunct; NASH benefit | Weight gain, edema, fracture risk, bladder cancer concern |
| SGLT2 inhibitors | ↑ Glucosuria → ↓ glucotoxicity, ↑ insulin sensitivity | T2DM, HF, CKD | Genital mycotic infections, euglycemic DKA risk |
| GLP-1 RAs | ↑ Insulin, ↓ glucagon, ↓ appetite, ↓ gastric emptying | T2DM, obesity, CV risk reduction | Nausea, cost; semaglutide/liraglutide approved for obesity |
| DPP-4 inhibitors | ↑ Endogenous GLP-1 | T2DM | Weight neutral, modest efficacy |
